Correction to “Discovery of Novel 5-Cyano-3-phenylindole-Based LSD1/HDAC Dual Inhibitors for Colorectal Cancer Treatment”

Abstract

In our study investigating the impact of target compound 20c alongside positive control drugs (ORY-1001 and SAHA) on the expression levels of HDAC and LSD1 substrate proteins─specifically, Ac-tubulin, Ac-H3, Ac-H4, H3K4me1, H3K4me2, and H3K4me3─we conducted a series of experiments on different tumor cell lines, including HCT-116 and HT-29 cells. Regrettably, during the assembly of Figure 7 in the original manuscript, we inadvertently used an incorrect image for H3K4me1 and H3 in Figure 7E. Upon a recent and thorough review of the original manuscript and raw data, we identified this error and have now replaced the incorrect image with the correct one in the revised Figure 7. All authors have agreed to the change. The corrected figure still demonstrates that compound 20c significantly upregulates the expression level of H3K4me1, and this correction do not alter the scientific conclusions of our study in any way. Figure 7. Compound 20c simultaneously inhibited LSD1 and HDAC activities in HCT-116 and HT-29 cells. (A-D) Western blot analysis of the effects of compound 20c on the expression levels of Ac-tubulin, Ac-H3, Ac-H4, and H3 in HCT-116 and HT-29 cells; (E–H) Western blot analysis of the effects of compound 20c on the expression levels of H3K4me1, H3K4me2, H3K4me3, LSD1, and H3 in HCT-116 and HT-29 cells; (I, J) CETSA of LSD1 with 20c at 5.0 μM in HCT-116 and HT-29 lysates for 6 h; (K) CETSA of LSD1 with 20c at different concentrations (1.25, 2.5, and 5.0 μM) in HCT-116 lysates for 6 h; (L) Western blot analysis of the effects of compound 24 on the levels of H3K4me1, H3K4me2, and Ac-H3. We sincerely regret any confusion this may have caused and appreciate the readers’ understanding as we take the necessary steps to ensure the accuracy and integrity of our research. This article has not yet been cited by other publications.